Navigation Links
NexBio Presents Data at ACAAI 2010 Demonstrating Mechanism of Action for Improvement in Airway Function by DAS181 (Fludase®*)
Date:11/11/2010

SAN DIEGO, Nov. 11, 2010 /PRNewswire/ -- NexBio, Inc. announced the presentation of new data at the 2010 annual American College of Allergy, Asthma, and Immunology in Phoenix, Arizona.  The presentation was entitled "DAS181 (Fludase®), a Sialidase, Decreases Airway Resistance by Modulating Muscarinic Receptor Signaling."

DAS181 (Fludase®) is an investigational broad spectrum host-targeting antiviral drug candidate undergoing clinical development for the treatment and prevention of Influenza-Like Illness caused by all strains of influenza and parainfluenza (PIV).  These new data show that, independent of its antiviral activity, and by a different mechanism of action, DAS181 may have benefit for airway diseases such as asthma and COPD.

NexBio presented nonclinical data at ACAAI 2009 from studies in three animal models of asthma, demonstrating that DAS181 inhibits airway hyperreactivity characteristic of asthma, as well as airway inflammatory cells and airway mucus, characteristic of chronic airway inflammatory conditions such as COPD.  The current presentation at 2010 ACAAI builds on this prior work by elucidating a key mechanism of action.  The data demonstrate that desialylation of airway muscarinic receptors in both in vivo and in vitro models unexpectedly reduces muscarinic pathway signaling. DAS181 given to mice once daily for three days, at doses lower than those used for antiviral treatment, leads to significantly reduced airway resistance in response to challenge by methacholine.

"The data suggest that DAS181 may have a dual benefit for patients with airway disease who become infected with the respiratory viruses influenza and parainfluenza, as DAS181 may fight infection while simultaneously controlling the underlying airway disease.  These patients are at high risk for exacerbations of their airway disease, as was seen during the 2009 Pandemic, and it is possible that DAS181 may l
'/>"/>

SOURCE NexBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses
2. NexBio(R) Presents DAS181 (Fludase(R)*) Potently Inhibits Novel Swine-Origin A(H1N1) and NAI-Resistant Influenza Viruses, at ICAAC 2009
3. Access Pharmaceuticals Presents CobOral™ Insulin Research at 10th Annual Diabetes Technology Meeting on November 11-13, 2010
4. AAOS Clinical Guideline for Treating Spinal Compression Fractures Presents More Questions Than Answers for Medical Community
5. Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
6. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
7. Spectros Presents New Clinical Studies Using T-Stat VLS Tissue Oximeter at Anesthesiology 2010
8. Sanofi Pasteur Presents Phase III Data on Intradermal Microinjection of Influenza Vaccine
9. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
10. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
11. Caligor Rx Presents Penn and USciences Bioethicist at the 2010 Clinical Trial Supply East Coast Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... -- On September 25 to 26, 2014, ... and manufacturing - MEDTEC China  - will mark its ... Convention Center, bringing together close to 300 leading global ... latest medical-grade raw materials, parts and processing technologies. ... free visitor pre-registration to be completed. To date, more ...
(Date:9/16/2014)... , Sept. 16, 2014 Northwest Biotherapeutics (NASDAQ: ... developing DCVax® personalized immune therapies for solid tumor cancers, ... to receive formal designation as a "Promising Innovative Medicine" ... (EAMS) launched in the UK in April 2014.  A ... for early access approval under the EAMS.  ...
(Date:9/16/2014)... 2014  Synereca Pharmaceutics, Inc. (SPI), a ... drugs that restore or increase the effectiveness ... million convertible debt financing. Accele Venture Partners, ... Accele Biopharma, Inc., led the financing with ... private not-for-profit corporation focused on growing innovative ...
Breaking Medicine Technology:MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 3NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 5Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4
... France, July 10 Ipsogen SA,(Alternext: ALIPS) today reported ... Therapy of Early Breast Cancer indicated for the first,time ... adjunct to the,histological grade. These new guidelines, published online ... European and US experts on,early breast cancer treatment that ...
... , KENILWORTH, N.J., July 9 Schering-Plough Corporation (NYSE: ... the company,s country operation in Japan, has received marketing ... for the treatment of bronchial asthma in adults.(1) , ... of the ASMANEX TWISTHALER in Japan," said Thomas P. ...
Cached Medicine Technology:Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer 2Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer 3ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients 2ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients 3ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients 4
(Date:9/16/2014)... the right balance of nitrogen, phosphorus and potassium is ... State University study finds. , A review of data ... other regions showed that high yields were linked to ... nutrients at specific ratios - nitrogen and phosphorus at ... a ratio of 1-to-1. These nutrient uptake ratios were ...
(Date:9/16/2014)... PA (PRWEB) September 16, 2014 AcousticSheep ... are preparing to launch RunPhones® Wireless, their latest version ... inside a sport-style headband for active people seeking a ... sport headphones on the market and will be ... new RunPhones® Wireless has all of the same great ...
(Date:9/16/2014)... Tara Haelle HealthDay ... -- About 14.5 million U.S. cancer survivors are alive ... American Association for Cancer Research reported Tuesday. These ... include nearly 380,000 survivors of childhood cancer, according to ... in prevention, identification, research and treatment of cancer and ...
(Date:9/16/2014)... September 16, 2014 Novatus, a leading ... new office in London, UK, and appointed Jim Curran ... Europe, the expansion will allow Novatus to target growing ... European customers. , “Novatus is excited ... London is an ideal location to establish our European ...
(Date:9/16/2014)... DC September 16, 2014 The ... coherence tomography (OCT) in primary percutaneous coronary ... annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. ... TCT is the world,s premier educational meeting ... OCT uses light emitted from an intravascular ...
Breaking Medicine News(10 mins):Health News:Boosting global corn yields depends on improving nutrient balance 2Health News:Boosting global corn yields depends on improving nutrient balance 3Health News:RunPhones® Prepares to Launch Their New Highly Anticipated Wireless Headphones 2Health News:RunPhones® Prepares to Launch Their New Highly Anticipated Wireless Headphones 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 4Health News:Novatus Expands European Operations with a New Office in London 2Health News:Results of OCT STEMI trial reported at TCT 2014 2
... to lead Diabetes Sales, Managed Care and Government ... ... Novo Nordisk, a,healthcare company with an 85-year history of innovation ... Pamela Harris as,vice president for Diabetes Sales, Managed Care and ...
... Two-Week Eye Health Program,in Mandalay, NEW YORK, Feb. ... and the Mandalay Eye and ENT Hospital, ORBIS,International, a ... to Myanmar to conduct its ninth Flying Eye,Hospital program ... February,25 to March 7, 2008., Working together with ...
... drive to digitize data creates need for 99.999% ... ... virtually all healthcare,record keeping and patient care functions converting to ... grade" servers that provide the extreme reliability healthcare,practices need to ...
... rarely detected before it has grown large enough to impair ... disease to fight, especially since chemotherapy is not very effective. ... Faingold may open the door for very promising new treatment ... the cover of the February 2008 issue of Clinical Cancer ...
... Frank E. Staggers, Sr.,M.D. of Oakland, Calif., is a ... Excellence in Volunteerism. Presented by the American Medical,Association (AMA) ... commitment to volunteer medical care to those without access,to ... the award in,association with the Pfizer Medical Humanities Initiative., ...
... Joyce D. Kirkland Essien,M.D., M.B.A., of Atlanta, is ... Presented by the American Medical Association (AMA),Foundation, the award ... the U.S. The AMA Foundation presents the award in,association ... will be presented on Monday, March 31st, at the ...
Cached Medicine News:Health News:Novo Nordisk Consolidates U.S. Diabetes Sales Leadership Under Single Vice President 2Health News:ORBIS International's Flying Eye Hospital Returns to Myanmar 2Health News:Stratus Medical Grade Servers Deliver 24/7 Online Information Access and Application Availability 2Health News:Stratus Medical Grade Servers Deliver 24/7 Online Information Access and Application Availability 3Health News:HSP90: New point of view on melanoma of the eye, at the MUHC 2Health News:AMA Foundation Honors Oakland, California Physician for Volunteerism 2Health News:AMA Foundation Honors Atlanta Physician for Increasing Access to Health Care in the U.S. 2
Ungrooved permanent silicone strip. Indications: For trapdoor procedure. Overall length: 125 mm, 4.9 inches....
Ungrooved permanent silicone strip. Indications: For trapdoor procedure. Overall length: 125 mm, 4.9 inches....
Used with Double Tantalum Clip (250 style) E5381 852. Overall length: 7.0 mm....
Concave inner surface to conform to the globe. Indications: Wide scleral bed. Outside diameter 32 mm....
Medicine Products: